身体组成和血总tau,神经纤维光链和粉样β:基于人口的研究
Tosca O E de Crom1, Mohsen Ghanbari1, Trudy Voortman1
1Department of Epidemiology Erasmus MC University Medical Center Rotterdam the Netherlands.
Alzheimer's & dementia (Amsterdam, Netherlands)
|January 17, 2024
概括
在老年人中,较高的体重可能不会防止痴呆症. 身体成分会影响神经退行性标记物,如总tau和神经纤维光链 (NfL),这表明它对大脑健康有明显的影响.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 生物标志物 生物标志物
背景情况:
- 矛盾的是,老年人体质量较高与痴呆症风险较低有关.
- 这种关联可能会被与年龄相关的瘦质量损失或研究局限性所混.
- 临床前痴呆症标志物提供了一种潜在的方法来澄清这种关系.
研究的目的:
- 调查人体组成和神经退行症的血生物标志物之间的横截面关联.
- 探索身体质量,脂肪质量和肌肉质量如何与总,NfL和粉样蛋白-β等标记物相关.
主要方法:
- 利用了3408名没有痴呆症的参与者在基于人口的鹿特丹研究 (2002-2005) 的数据.
- 使用身体组成分析测量全身,脂肪和肌肉质量.
- 评估了总,神经丝光链 (NfL),粉样蛋白-β 40 (Aβ40) 和粉样蛋白-β 42 (Aβ42) 的血水平.
- 使用线性回归模型来确定关联.
主要成果:
- 全身和脂肪质量与血总比值正相关.
- 身体构成测量 (全身,脂肪和肌肉质量) 与血NfL相反相关.
- 瘦身量显示与血氨基酸β 40 (Aβ40) 的反向关联.
- 没有发现身体成分和血氨基酸β 42 (Aβ42) 之间的显著关联.
结论:
- 身体成分似乎对特定的神经退行性途径产生不同影响.
- 研究结果表明,脂肪和瘦肉质可能通过不同的机制影响神经退行.
- 需要进一步的研究来阐明身体组成和老化中的大脑健康之间的复杂相互作用.
相关概念视频
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


